Strong Results and Improved Guidance Lifted Artivion (AORT)

Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets continued their upward trajectory in the quarter, with the S&P 500 Index surging 8.12%. Class A shares of the fund underperformed the Russell 2500 Growth Index during the third quarter of 2025. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its third-quarter 2025 investor letter, Alger Weatherbie Specialized Growth Fund highlighted stocks such as Artivion, Inc. (NYSE:AORT). Artivion, Inc. (NYSE:AORT) is a global manufacturer and distributor of medical devices and implantable human tissues. The one-month return of Artivion, Inc. (NYSE:AORT) was 6.90%, and its shares gained 69.32% of their value over the last 52 weeks. On October 28, 2025, Artivion, Inc. (NYSE:AORT) stock closed at $45.26 per share, with a market capitalization of $2.136 billion.

Alger Weatherbie Specialized Growth Fund stated the following regarding Artivion, Inc. (NYSE:AORT) in its third quarter 2025 investor letter:

"Artivion, Inc. (NYSE:AORT) manufactures, processes, and distributes medical devices and preserved tissues used in cardiac and vascular surgeries for patients with aortic disease. The business spans medical devices and preservation services. Shares contributed positively during the quarter after Artivion reported a strong fiscal second-quarter earnings and raised its full-year outlook. Management pointed to renewed momentum in its mechanical valves and continued uptake of a new aortic stent graft, and emphasized operating leverage as the business scales. Investor confidence was further supported by progress on the U.S. clinical pathway for an aortic arch device."

Artivion, Inc. (NYSE:AORT) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 21 hedge fund portfolios held Artivion, Inc. (NYSE:AORT) at the end of the second quarter, up from 18 in the previous quarter. Artivion, Inc. (NYSE:AORT) reported total revenues of $113 million for the second quarter of 2025, an increase of over 14% compared to Q2 of 2024. While we acknowledge the potential of Artivion, Inc. (NYSE:AORT) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.